Author Archives: admin


A New FMI Report Forecasts the Impact of COVID-19 Pandemic on Stem Cell Therapies Market Growth Post 2020 – The Scarlet

With 1000+ market research reports and 1 billion+ data points, Future Market Insights (FMI) serves each and every requirement of the clients operating in the global healthcare, pharmaceuticals, and medical device industries. FMI deploys digital intelligence solutions to offer compelling insights to report buyers that help them in overcoming market challenges, especially at the time of a crisis. Our dedicated team of professionals performs an extensive survey for gathering accurate information associated with the market.

FMI, in its upcoming business report, elaborates the historical and current scenario of the Stem Cell Therapies in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Stem Cell Therapies report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Stem Cell Therapies

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Stem Cell Therapies. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Stem Cell Therapies.

Following governments measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMIs report includes an interesting chapter on preliminary impact of the COVID-19 on the Stem Cell Therapies. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Why Choose Future Market Insights

Discounted prices for new customers! Offer expires soon!

Request Report [emailprotected] https://www.futuremarketinsights.com/reports/sample/rep-gb-1087

Stem Cell Therapies market: segmentation

To analyze the Marketing Stem Cell Therapies effectively and efficiently, the information has been segregated into key segments and sub-segments.

On the basis of treatment:

On the basis of application:

Stem Cell Therapies: Competition Analysis

The FMIs study presents a comprehensive analysis of global, regional, and country-level players active in the Stem Cell Therapies. Competitive information detailed in the Stem Cell Therapies report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Stem Cell Therapies report.

Key players covered in the report include:

Request Methodology of this Report @ https://www.futuremarketinsights.com/askus/rep-gb-1087

Important Questions Answered in the Stem Cell Therapies Report

Key Offerings of the Report

About Us Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us Mr. Abhishek Budholiya 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F: +1-845-579-5705 T (UK): + 44 (0) 20 7692 8790 Sales: [emailprotected] Press Office: [emailprotected] Blog: Market Research Blog Website: https:www.futuremarketinsights.com

Excerpt from:
A New FMI Report Forecasts the Impact of COVID-19 Pandemic on Stem Cell Therapies Market Growth Post 2020 - The Scarlet

Cell Harvesting Market 2018 Analysis Of Production, Future Demand, Sales And Consumption Research Report To 2023 – The Scarlet

The global market for cell harvesting should grow from $885 million in 2018 to reach $1.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.3% for the period of 2018-2023.

Report Scope:

The scope of the report encompasses the major types of cell harvesting that have been used and the cell harvesting technologies that are being developed by industry, government agencies and nonprofits. It analyzes current market status, examines drivers on future markets and presents forecasts of growth over the next five years.

The report provides a summary of the market, including a market snapshot and profiles of key players in the cell harvesting market. It provides an exhaustive segmentation analysis of the market with in-depth information about each segment. The overview section of the report provides a description of market trends and market dynamics, including drivers, restraints and opportunities. it provides information about market developments and future trends that can be useful for organizations, including wholesalers and exporters. It provides market positionings of key players using yardsticks of revenue, product portfolio, and recent activities. It further includes strategies adopted by emerging market players with strategic recommendations for new market entrants. Readers will also find historical and current market sizes and a discussion of the markets future potential. The report will help market players and new entrants make informed decisions about the production and exports of goods and services.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/11685

Report Includes:

41 data tables and 22 additional tables Description of segments and dynamics of the cell harvesting market Analyses of global market trends with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023 Characterization and quantification of market potential for cell harvesting by type of harvesting, procedure, end user, component/equipment and region A brief study and intact information about the market development, and future trends that can be useful for the organizations involved in Elaboration on the influence of government regulations, current technology, and the economic factors that will shape the future marketplace Key patents analysis and new product developments in cell harvesting market Detailed profiles of major companies of the industry, including Becton, Dickinson and Co., Corning, Inc., Fluidigm Corp., General Electric Co., Perkinelmer, Inc., and Thermo Fisher Scientific, Inc.

Summary

Stem cells are unspecialized cells that have the ability to divide indefinitely and produce specialized cells. The appropriate physiological and experimental conditions provided to the unspecialized cells give rise to certain specialized cells, including nerve cells, heart muscle cells and blood cells. Stem cells can divide and renew themselves over long periods of time. These cells are extensively found in multicellular organisms, wherein mammals, there are two types of stem cells embryonic stem cells and adult stemcells. Embryonic stem cells are derived from a human embryo four or five days old that is in the blastocyst phase of development. Adult stem cells grow after the development of the embryo and are found in tissues such as bone marrow, brain, blood vessels, blood, skin, skeletal muscles and liver. Stemcell culture is the process of harvesting the exosomes and molecules released by the stem cells for the development of therapeutics for chronic diseases such as cancer and diabetes. The process is widely used in biomedical applications such as therapy, diagnosis and biological drug production. The global cell harvesting market is likely to witness a growth rate of REDACTED during the forecast period of 2018-2023.The value of global cell harvesting market was REDACTED in 2017 and is projected to reach REDACTED by 2023. Market growth is attributed to factors such as increasing R&D spending in cell-based research,the introduction of 3D cell culture technology, increasing government funding, and the growing prevalence of chronic diseases such as cancer and diabetes.

The growing incidence and prevalence of cancer is seen as one of the major factors contributing to the growth of the global cell harvesting market. According to the World Health Organization (WHO), cancer is the second-leading cause of mortality globally and was responsible for an estimated 9.6 million deaths in 2018. Therefore, there is an increasing need for effective cancer treatment solutions globally. Cell harvesting is the preferred method used in cancer cell-related studies including cancer cell databases (cancer cell lines), and other analyses and drug discovery in a microenvironment. The rising prevalence of such chronic diseases has led governments to provide R&D funding to research institutes and biotechnology companies to develop advanced therapeutics. Various 3D cell culture technologies have been developed by researchers and biotechnology companies such as Lonza Group and Thermo Fischer Scientific for research applications such as cancer drug discovery. The application of cell culture in cancer research is leading to more predictive models for research, drug discovery and regenerative medicine applications.

Platelet-rich plasma (PRP) therapy, a new biotechnology solution that has a heightened interest among researchers in tissue engineering and cell-based therapies, has various applications in the treatment of tissue healing in tendinopathy, osteoarthritis and muscle injury. It has been conventionally employed in orthopedics, maxillofacial surgery, periodontal therapy and sports medicines. PRP therapy can be used in the treatment of fat grafting, acne scars, and hair regrowth.

Major factors driving market growth include increasing healthcare costs and the high rate of adoption for modern medicines in emerging economies such as China and India. It has been estimated that India will witness a CAGR of REDACTED in the cell harvesting market during the forecast period. The active participation of foreign pharmaceutical companies has tapped the Indian healthcare sector with a series of partnerships and mergers and acquisitions, which in turn is positively impacting the growth of the market in this region. Consistent development and clinical trials for stem cell therapies, plus contribution from the government and private sectors through investments and cohesive reimbursement policies in the development of cancer biomarkers, is further fueling market growth. InSweden, a research team at Lund University has developed a device to collect fluid and harvest stem mesenchymal stem cells (MSCs). The device is developed with 3D-printed bio-inert plastics which, when used by doctors, can result in the safe extraction of fluids (medical waste) from the patients body. The liquid is then passed through a gauze filter for purifying thoroughly and MSCs are separated from the fluid by centrifugation and are grown in culture.

Follow this link:
Cell Harvesting Market 2018 Analysis Of Production, Future Demand, Sales And Consumption Research Report To 2023 - The Scarlet

Sophie (5) lit up a room and was a little inspiration – New Ross Standard

Sophie Walsh, who left this world on Tuesday (18th) aged five, was a ray of sunshine who brightened up the lives of everyone who was fortunate enough to meet her.

Sophie, like most children her age, was due to start school this week. After a long, courageous battle with cancer, she succumbed to the illness that afflicted her over three years at Crumlin Children's Hospital on Tuesday.

Born a perfectly healthy child on July 3, 2015, into a loving home, her parents Sandra and Thomas were overjoyed to bring her back to her freshly decorated room in Lacken Valley.

Sophie met all her milestones but just before her second birthday, Thomas and Sandra sensed there was something wrong.

'She was going off her food. We went to doctors, hospitals a couple of times, both in Waterford and Wexford. Then back to the GP and CareDoc. They were all putting it down as a viral thing that would run its course but nothing seemed to be getting any better,' Thomas said.

They brought Sophie to CareDoc one Sunday evening and a doctor noticed a lump which was examined at University Hospital Waterford and the next day Sophie, Thomas and Sandra left for Crumlin, the first of many visits.

'Our lives changed overnight,' Sandra said. 'Our consultant sat us down and laid out a treatment plan which was going to be up to two years. The doctors said it was going to be an intensive time.'

Sophie was diagnosed with neuroblastoma, a cancer of the central nervous system.

The prognosis was 50/50 as Sophie had an amplified version of the illness which made it harder to treat. Thankfully Sophie responded very well to treatment and after a few weeks her energy levels started improving.

'She was back to being normal, except without the hair. She completed ten rounds of chemotherapy and had a break over Christmas and had surgery for her tumour, from which she recovered well. She had her own stem cell transplant in March,' Thomas said.

Throughout, Sandra and Thomas were staying in the Ronald McDonald House near Crumlin on and off, their every waking moment by her side as Sophie recovered from the transplant and had 14 rounds of radiotherapy in St Luke's, being administered a general anaesthetic every day.

She recovered from her treatment and had five rounds, once a month of immune-therapy.

'She finished that in January 2019 and then she was finished. There was no evidence of disease.'

Throughout Sophie couldn't enjoy the social interactions other children take for granted.

'She couldn't have a normal childhood as she was susceptible to infections. She could have cousins and friends around (sometimes). When we could, we did. She was in isolation for 100 days after her bone marrow transplant. Sophie made loads of friends at Crumlin. There were families from throughout Ireland we met up there and became good friends with. She was in Tir na ng playschool (when she could). She was looking forward to starting school.'

Throughout the spring of 2019 Sophie was in great health. 'Everything was going good. She loved her dolls. She loved watching Youtube. Watching kids playing with toys. She loved to play. When she was feeling up to it she wanted to play and when she wasn't she watched TV.'

Recalling a really happy child, an old soul in a child's body, her parents said she was ahead of her years in terms of her conversations and speech. 'She was around adults a lot between nurses and doctors. She had a great imagination. She could pick up a book and even if she couldn't understand the words she'd make up a story from the pictures.'

Sandra said: 'She was very witty; very quick off the mark. She was stubborn as well. If she didn't want to do anything you couldn't change her mind; it was set and that was it.

'We often said she was an old person wrapped up in a small person's body.'

Sophie enjoyed a magical trip to Disneyland with her parents, revelling in meeting Mickey Mouse and all the Disney characters she had seen on TV.

'She loved it!' they said.

Having enjoyed great health all spring of last year, something showed up in a routine scan midway during the summer.

'It was very small and they couldn't be 100 per cent. We had to wait and see what happened. She did a biopsy in September which confirmed she had relapsed and, at that stage, we knew she would have a very poor prognosis of five or six per cent. But we didn't give up hope because she had such a good response the first time around so we thought she could do it again. She had a tough road.'

Due to the location of the cancer within the femur and her tender age, the bone broke the day after the biopsy.

Undeterred Sophie went around in her buggy to trick or treat that Hallowe'en, totally embracing the chance to get dressed up.

'She adapted so well to every challenge. She had a nice Christmas.'

Sophie continued getting treatments after Christmas. 'The treatment she was on wasn't working as well as they liked and there was more progression on it. They switched her onto a different treatment again in February. We were running out of options at this stage.'

Sophie's condition was being kept at bay with the chemotherapy. She still had a good quality of life, but less energy.

'We had been told that the chemo would only work for so long and the cancer can find ways around it and gets used to it. We were always hoping for a miracle and that something would come along.'

Sophie enjoyed a great fifth birthday with friends and family in the garden.

A few weeks later, Aoibhinn's Pink Tie charity staff arranged a princess party at the Horse & Hound for her.

'She had wanted to meet Elsa and Anna. She had her cousins and there was face painting. That was her last good day.'

That evening Sophie started complaining of pain and her leg became more and more swollen.

She was admitted to University Hospital Waterford the following week and a CT scan showed quick progression of the tumour.

Sophie was transferred to Crumlin to help her pain management.

She died on Tuesday, August 18.

'It happened so suddenly. She was tired from treatment. There was one of us with her at all times; we took it in turns.'

Both Thomas and Sandra, who have been out of work since the diagnosis to care for Sophie, said: 'Everything changed so quickly and with the diagnosis and the prognosis we didn't want to wait a second. We didn't want to be looking back in five or ten years time that we had missed out. We had three amazing years. It was just the three of us, especially during lockdown it was nice just to have that time, the three of us.'

They praised the nursing staff of the hospitals Sophie as cared in.

Thomas said: 'Throughout, the whole community were amazing; especially neighbours and local businesses. Even just in terms of support. She was treated like a mini celebrity in The Bakehouse and O'Briens. Everywhere she went on the town everybody knew her and was so good to her. She was a little character as well. Every day she'd say something that made you laugh. She wasn't always in good form but she could change so quick. She would never dwell on things and never left her illness define her; she just kinda got on with it and never talked about it.'

Some of the nurses attended Sophie's funeral, as did staff members from McDonald's in Waterford, a favourite destination for Sophie.

'The nurses left off balloons outside for her. They were so good to her. If she wanted a dance party they held a dance party, copying her moves. The Dunbrody ship was lit up gold for Sophie, ahead of cancer awareness month in September. She would have been starting school this week. We had picked a school and she was looking forward to starting big school.'

Sandra and Thomas left the house on Friday morning for their daughter's funeral.

'All of the neighbours were lined up on either side of the road. We had a garda escort down. Fr Tom Orr gave a lovely, personal eulogy. He was excellent to us and even called to Crumlin to see her. Members of the United Striders stood as guards of honour, as did Urban Gym and Tr na Ng staff.'

'You Are My Sunshine' rang out from the speakers at her funeral Mass, where not a dry eye could be found.

Sophie was laid to rest in St Stephen's Cemetery, not far from her home.

The family want to thank everyone involved in sharing their love of Sophie on Friday, from the guards of honour to their neighbours and the wider community.

Sandra and Thomas said the Ronald McDonald House and Aoibhinn's Pink Tie charities were tremendously supportive throughout the three years.

'When a diagnosis comes, it's rushed and people arrive at John's Ward [in Crumlin] with just the clothes on their back. Even to have a toothpaste and brush.'

They recall in hushed tones, five years of happy memories with Sophie. 'Just being so happy; a family - the three of us. She could just light up a room; she had a presence about her. She would make anybody laugh and left a lasting impression on people who were just drawn to her. She could come out with anything. She told it as it was.'

They spoke of a child who inspired them to have a positive outlook on life and cherish each day as it comes, no matter what.

'For a five-year-old she was so happy go lucky. She inspired us. One day in the hospital she was colouring for the nurses and started colouring squiggles. I said why aren't you doing it properly and she said "life is too boring to just stay between the lines". There is a lot you can learn from a five-year-old, about outlook on life and how to deal with adversity. If Sophie spiked a temperature it means a few days in hospital and there was never any complaining.'

Sophie is dearly missed by Thomas and Sandra, her grandfathers Pat and Billy, aunts, uncles, cousins, extended family and friends.

New Ross Standard

Follow this link:
Sophie (5) lit up a room and was a little inspiration - New Ross Standard

Rare group of HIV patients don’t need drugs to suppress virus due to way it integrates in their DNA – Brinkwire

A woman diagnosed with HIV almost 30 years ago may have been cured of the virus without taking drugs or having a bone marrow transplant.

Scientists have studied Loreen Willenberg for decades, with the 66-year-old insisting she has never taken medication to keep the virus at bay. Doctors say her body fights the infection naturally.

But now academics claim she can be added to the list of cured HIV patients, next to theBerlin patient Timothy Ray Brown and the London patientAdam Castillejo.

Both Mr Brown, 54, and Mr Castillejo, 40, had cancer and were given a bone marrow transplant from adonor with HIV-resistant genes to wipe out their disease and the AIDS-causing virus in one fell swoop.

Ms Willenberg who was diagnosed in 1992 and is considered an elite controller because she possesses the rare ability to suppress the virus by itself never had the risky treatment.

Researchers at the Ragon Institute of MGH, MIT and Harvard found no traces of HIV in the Californian woman through standard tests.

Advanced technology that analysed 1.5billion of Ms Willenbergs blood cells found tiny quantities of the virus, meaning she isnt HIV-free. But the doctors revealed her immune system had rendered the leftover traces incapable of reproducing.

Dr Sharon Lewin, director of The Peter Doherty Institute for Infection and Immunity in Australia, told the New York Times: She could be added to the list of what I think is a cure, through a very different path.

Another 63 patients not on anti-retroviral drugs were also found to have traces of HIV that were unable to reproduce.

The team, whose work was published in the journal Nature, say the findings provide evidence that these people have achieved a functional cure.

Elite controllers are only believed to account for 0.5 per cent of the 37million people living with HIV across the world.

Researchers found that, because of where these patients have the virus encoded in their DNA, the pathogen is unable to make copies of itself. Thiskeeps the virus below detectable levels, which makes it untransmissible.

Once a person contracts HIV, the virus sets about attacking and destroying immune cells that normally protect the body from infection.

In the last decade, doctors have gained a much improved understanding of how to control HIV. The rate of deaths from the disease has plummeted since the peak of the AIDS epidemic in the early 1980s.

It is treatable and doctors recommend taking a combination or cocktail of drugs known as antiretroviral therapy, or ART.

Within six months of taking the medication once a day, a persons viral load will be virtually undetectable, but the body wont be completely rid of it.

This is because the virus hides in the body by integrating its genetic material into DNA and forming whats known as a latent reservoir.

But ART which can cause nausea, diarrhoea, headaches and fatigue isnt able to destroy these reservoirs but if an HIV patient ceases taking the cocktail, the virus can start making copies of itself again.

Elite controllers have latent reservoirs, but they dont need to take drugs to stop the virus from spreading throughout the body.

They naturally maintain what other people need ART to do, co-author Dr Mathias Lichterfeld, an infectious disease physician at Ragon, told HealthDay.

For the study, the team looked at blood samples from 64 elite controllers and 41 HIV patients taking ART.

Results showed that, in elite controllers, HIV genetic material was found in so-called gene deserts of the DNA. These are where there is little gene activity so the virus is unable to make copies of itself and instead remain in a blocked and locked state.

Lead author Dr Xu Yu, an associate professor of medicine at Harvard Medical School, said: This positioning of viral genomes in elite controllers is highly atypical.

In the vast majority of people living with HIV-1, HIV is located in the active human genes where viruses can be readily produced.

Dr Yu calls this a functional cure, which occurs when a virus is still in the body but can be controlled without medication.

The researchers believe this is because, in the early days of infection, the immune systems of elite controllers killed the virus after it integrated into DNA regions with a great deal of gene activity.

The team says the findings could lead to a cure, either by creating drugs that replicate the phenomenon of elite controllers or that eliminate HIV thats integrated in parts of the DNA that have substantial gene activity.

Elite controllers carry a mutation of CCR5, which prevents it from expressing, which essentially blocks the gene altogether. Experts say the genetic quirk has descended from northern Europeans.

The study comes after a Brazilian man in his mid-30s with HIV went into long-term remission after treatment with drugs and vitamin B3.

Doctors last month revealed the case of the Sao Paolo patient, who is understood to be the first HIV patient in the world to go into remission following pharmaceutical treatment.

And scientists last year revealed that a third HIV-positive patient in Germany may be free of the virus after undergoing the risky bone-marrow transplant.

But neither the Sao Paolo patient orthe Dsseldorf patient had been free of the virus for long enough to be considered cured.

For example, cancer patients have to be in remission for five years before they are labelled as cured.

Unfortunately, the Berlin and London patients cases do not change the reality much for the millions of people living with HIV.

The treatment is unlikely to have potential on a wider scale because both Mr Castillejo and Mr Ray Brown were given stem cells to treat cancer, not HIV.

Stem cell and bone marrow transplants are life-threatening operations with huge risks. Dangers lie in the patient suffering a fatal reaction if substitute immune cells dont take.

Mr Ray Brown, who is from Seattle but was treated in Germany, has been HIV-free for 12 years without medication.

But Mr Castillejo, whose mental health had spiralled drastically over the years and even led him to consider ending his life, was only treated in 2016.

See the rest here:
Rare group of HIV patients don't need drugs to suppress virus due to way it integrates in their DNA - Brinkwire

Hematopoietic Stem Cell Transplantation (HSCT) Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2022 -…

The global Hematopoietic Stem Cell Transplantation (HSCT) market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Hematopoietic Stem Cell Transplantation (HSCT) market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Hematopoietic Stem Cell Transplantation (HSCT) market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Hematopoietic Stem Cell Transplantation (HSCT) market. The Hematopoietic Stem Cell Transplantation (HSCT) market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2773144&source=atm

segment by Type, the product can be split into Allogeneic Autologous Market segment by Application, split into Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2773144&source=atm

The Hematopoietic Stem Cell Transplantation (HSCT) market research covers an exhaustive analysis of the following data:

The Hematopoietic Stem Cell Transplantation (HSCT) market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2773144&licType=S&source=atm

The global Hematopoietic Stem Cell Transplantation (HSCT) market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

More here:
Hematopoietic Stem Cell Transplantation (HSCT) Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2022 -...

Global Cell Proliferation Kit Market Insights And Extensive Research (2020-2025) : Biological Industries, Thermo Fisher – The Daily Chronicle

Eon Market Research Publish New Market Report On- Cell Proliferation Kit Market 2020 Global Analysis, Size, Share, Trends and Growth, Forecast 2025

The Cell Proliferation Kit Market Report also provides extensive research on the Top key players in this market and detailed insights into theircompetitiveness. Key business strategies such as acquisitions and acquisitions, alliances, collaborations, and contracts adopted by Top keyplayers are also recognized and analyzed in the report. For each Industry, the report recognizes competitors, product types, applications andspecifications, prices, Trends, and gross margins. The study analyzes the market in terms of revenue across all the major markets.

Market Summary :

Different Top key players such as Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich (Merck), BD Biosciences, GE, PerkinElmer, Millipoore (Merck), Bio-Rad, Biotium And More have been profiled to get better insights into the businesses. It offersdetailed elaboration on different Leading level industries which are functioning in global regions. Additionally, it gives detailedelaboration on different government rules, policies, and plans to understand the overall scope of the Cell Proliferation Kit Market. In the global Cell Proliferation Kit Market, various important aspects such as regional market insights, region-wise trends, country-level analysis,competitive landscape, company market share analysis, and key company profiles are covered. The latest Cell Proliferation Kit Market report fine-tunes thescope of typical characteristics with which vendors are reviewed. For reviewing the global Cell Proliferation Kit Market, the report uses varioustechniques such as surveys, interviews, and structured discussions with participants, end-users, and market leaders.

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures( Get Instant 10% Discount ):https://www.eonmarketresearch.com/sample/68568

Cell Proliferation Kit Market regional analysis covers the following regions North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Product Segment Analysis of the Global Cell Proliferation Kit Market are:

Colorimetric Detection Method Fluorescent Detection Method Other

Applications of the Global Cell Proliferation Kit Market are:

Clinical Industrial and Applied Science Stem Cell Research

Buy This Premium Report: https://www.eonmarketresearch.com/buy/68568

Research Objectives Of Cell Proliferation Kit Market:

* This report provides pin-point analysis for changing competitive dynamics

* It provides a forward-looking perspective on different factors driving or restraining the market growth

* It provides a six-year forecast assessed on the basis of how the market is predicted to grow

* It helps in understanding the key product segments and their future

* It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

* It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

Any Questions? Feel Free To Enquire Here. We will Put You On The Right Path: https://www.eonmarketresearch.com/enquiry/68568

Points To Buy This Market Report Covers:

* It will guide you in considering different perspectives on the market with the assistance of Porters five powers examination.

* Distinguish the new advancements, mark

* A valuation that each of these regions accounts for in the industry

Buyers who are searching for top-line data regarding Cell Proliferation Kit market can get benefit from this report as its an essential resource which covers market size data, textual and graphical analysis of market growth trends and other economic information. In the resulting part, the report describes industry sales channels, distributors, traders, dealers, appendix and data sources.

[ *** If You Have Any Special Requirements, Please Let Us Know And We Will Offer You The Report As You Want. *** ]

About Us:

Eon Market Research (EMR) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Eon Market Research offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Get in Touch with Us :

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

More here:
Global Cell Proliferation Kit Market Insights And Extensive Research (2020-2025) : Biological Industries, Thermo Fisher - The Daily Chronicle

Foetal cells are used to make the Oxford coronavirus vaccine. But they came from a foetus in 1973 – ABC News

Religious leaders have raised ethical doubts over one of Australia's primary coronavirus vaccine hopes because scientists have used foetal cells in its development.

Developers at Oxford University and pharmaceutical firm AstraZeneca are using cell lines from an electively aborted foetus in the vaccine candidate, with Anglican, Catholic and Greek Orthodox leaders questioning the practice.

But using foetal cells in vaccine development isn't new and the Catholic Church has previously expressed qualified support for the use of vaccines derived from these cells under certain circumstances.

We spoke to Bill Lott, a virologist at QUT's Institute of Health and biomedical innovation, to understand the role of foetal cells in vaccine development.

The foetal cells used in vaccine development are derived from a small number of foetuses which were legally terminated decades ago.

The Oxford vaccine uses HEK (human embryonic kidney) 293 cell lines, obtained from a female foetus in the Netherlands in 1973.

"We're using tissues that were from foetuses that were aborted 40, 50, 60 years ago," Dr Lott said.

"It doesn't require newly aborted foetuses."

While living human cells can only divide around 50 times, those foetal cells have been genetically modified so they can divide an infinite number of times.

"That's why we can use the cells that we harvested [decades ago] today," Dr Lott said.

"They're not the actual original cells, they've been immortalised and then propagated over the decades."

This means we'll never need to replace specimens used in development.

"Just by analogy, buying ivory is illegal [because] if you create a market for ivory, then it creates the demand to kill more elephants," Dr Lott said.

"In this case, that's not happening because these foetuses were aborted 60 years ago, 50 years ago, and using these immortalised tissues now is not going to create a need to go and get new ones."

In fact, scientists would prefer to keep using HEK 293 cell lines because they have been repeatedly tried and tested in a laboratory setting and found to be safe.

"When you're making a vaccine you require safety testing," Dr Lott said.

"If we went back and used a different cell type, you're throwing an unknown into the consideration.

"So that will severely slow down your ability to make these things.

"Using HEK 293, we've used it for decades and we know that it's safe."

This week, Australia's Deputy Chief Medical Officer Nick Coatsworth pointed out the use of foetal cells had been a "reality" in past vaccine development.

"The reality for vaccines is that they need cell cultures in order for us to grow them," he said.

"The human cell is a really important part of their development.

"There are strong ethical regulations surrounding the use of any type of human cell, particularly foetal human cells.

"This is a very professional, highly powered research unit at Oxford University.

"I think we can have every faith that the way they have manufactured the vaccine has been against the highest of ethical standards internationally."

Breaking down the latest news and research to understand how the world is living through an epidemic, this is the ABC's Coronacast podcast.

So, how do foetal cells help with vaccine development? Dr Lott explained they operate like a "vaccine factory".

First, scientists need to develop the vaccine candidate and then combine it with an adenovirus vector.

An adenovirus is a particular type of common virus that causes illnesses like bronchitis, pneumonia and a sore throat.

For instance, when you get a cold, you may be infected with an adenovirus, a coronavirus or a rhinovirus.

A vector is an organism that spreads infection by moving pathogens from one host to another.

So an adenovirus vector? "That's an adenovirus that has been sort of emptied out and then you put a different kind of genome in there to make protein," Dr Lott said.

The next step is to put the vaccine/adenovirus vector combination into a big vat of foetal cells.

"The viral vector infects these HEK 293 cells really, really efficiently," Dr Lott said.

"One reason why you use the HEK 293 is because you get essentially 100 per cent infection with the adenoviral vector.

"And what it does is it turns the HEK 293 cells into a vaccine factory."

What do we mean by "vaccine factory"? Dr Lott explains foetal cells begin producing "tons and tons of that modified adenovirus" which they then "spit out into the liquid bit of the cells" called the cell culture media.

"[The foetal cells] start cranking out this massive amount of modified adenovirus, and then you purify those things away from the cell tissue," he said.

"You pull the [cell] media off, and it's just going to be full of the vaccine and essentially no tissue.

"And that's what your vaccine is."

The foetal cells will operate as this "vaccine factory" regardless of whether the vaccine is effective or not so the next step generally involves animal and then human trials of varying scale.

Inherent in the whole process is stripping away the conditioned cell media, where the foetal cells are contained.

The head of the World Health Organization has warned we may never get a silver bullet for COVID-19. What could that future look like in Australia?

That means a successful vaccine developed using foetal cells will have no remnants of those cells in the final product.

"You purify the vaccine away from the cells that they were grown in, and then you destroy all the cells," Dr Lott said.

"So then you're going to take that liquid and you'll purify it some more, but there are not going to be any [foetal] cells in there.

"There's nothing left when it becomes the vaccine that gets delivered."

Foetal tissue has been used with innovative effect in various strands of medical research.

The difference is some of those processes require fresh foetal cells not the "immortalised" cells vaccine developers can use.

"The vaccine work is pretty straightforward," Dr Lott said.

"But cancer research, the research into the mechanisms of various things cystic fibrosis, haemophilia, rheumatoid arthritis that all required fresh foetal tissue."

Scientists studying Zika virus used foetal cells to discover that the virus crossed the placental membrane and caused brain damage in unborn foetuses.

"[That research] brought out a whole raft of therapies and protections for unborn foetuses [and] "saved a lot of lives, including [the lives of] unborn foetuses," Dr Lott said.

Foetal cell lines have been used in the development of various vaccines, including for chicken pox, Ebola, polio, rubella, shingles, Hepatitis A, and rabies.

Foetal tissue has also facilitated breakthroughs in the treatment of various medical issues including cystic fibrosis, haemophilia, IVF, Parkinson's and Alzheimer's diseases, AIDS, and spinal cord injuries.

Scientists have many different methodologies for developing vaccines and there are a variety of reasons why foetal cells aren't always used.

Billions are being poured into the race to find a coronavirus vaccine, with the winner owning a powerful political tool. During the last pandemic an Australian company got there first.

"Some of them don't use it because of ethical issues," Dr Lott said.

"Some of them don't use it because they're not using an adenovirus [vector], so they don't really need the HEK 293.

"And there are other [development] strategies.

"There's an mRNA strategy that's very popular.

"So some of them don't require it."

The development of a coronavirus vaccine was time critical because of the virus' devastating public health and economic impacts, Dr Lott said.

Therefore, it was important for scientists to diversify their methodologies in order to develop a vaccine as quickly as possible.

Both stem cells and foetal cells are critical to innovations in medical research but what's the difference between the two?

Dr Lott explains stem cells are basically the earliest iteration of a foetal cell before the cell differentiates itself into, for example, a hair cell, liver cell, eye cell or skin cells.

"A stem cell is simply a cell that can turn into a different cell types," Dr Lott said.

"That first embryonic stem cell can eventually turn into any kind of cell in your body.

"So you've got embryonic stem cells, and then you've got adult stem cells, and in between are the foetal stem cells [which] are partially differentiated.

"So foetal cells contain not only stem cells some of the foetal cells have already differentiated into their final cell type."

In 2005 and again in 2017, the Catholic Church expressed qualified support for the use of foetal-cell-derived vaccines but only if there was no available alternative.

A 2005 "moral reflection" issued by Pope Benedict XVI specifically addressed the issue.

"As regards the diseases against which there are no alternative vaccines which are available and ethically acceptable, it is right to abstain from using these vaccines if it can be done without causing children, and indirectly the population as a whole, to undergo significant risks to their health," the Pope wrote.

"However, if the latter are exposed to considerable dangers to their health, vaccines with moral problems pertaining to them may also be used on a temporary basis.

"We find a proportional reason, in order to accept the use of these vaccines in the presence of the danger of favouring the spread of the pathological agent."

In 2017, the life ethics arm of the Catholic Church issued a statement that: Catholic parents could vaccinate their children with a "clear conscience" that "the use of such vaccines does not signify some sort of cooperation in voluntary abortion".

Earlier this year and in the context of the coronavirus vaccine race, John Di Camillo, an ethicist with the National Catholic Bioethics Center, confirmed: "One is allowed to make use of [vaccine derived from foetal tissue] where there's a serious threat to the health or life of the individual, or of the greater population.

"This does not amount to a strictobligationto use it, but it certainly can be a legitimate choice in conscience if theres that serious reason, and there's no other reasonable alternative."

Follow this link:
Foetal cells are used to make the Oxford coronavirus vaccine. But they came from a foetus in 1973 - ABC News

Impact Of Covid-19 Outbreak On Global Automated Cell Culture Market Segment Analysis and 2020-2024 Future Projection Level – The Daily Chronicle

The research study Automated Cell Culture market 2020 available by ABRReports.com provides the detailed insights about factors affecting the market growth as well as detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global market

Access the PDF Sample Copy of the report at https://www.abrreports.com/industry-insights/global-automated-cell-culture-industry-market-research-2019?form=request-report-sample

The objective of the Study:

The key purpose of the study to track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Automated Cell Culture market. The report provides historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and the Rest of the World. The study delivers country-level analysis of the market with respect to the current market size and future perspective as well as country-level analysis of the market for segment by application, product type, and sub-segments country-level analysis of the market for segment by application, product type, and sub-segments

Access full research report with Table of Content at https://www.abrreports.com/industry-insights/global-automated-cell-culture-industry-market-research-2019

Key market segmentation as below:

Key players in global Automated Cell Culture market include: BD Tecan Trading Sartorius TAP Biosystems Cell Culture Company Eppendorf Merck KGaA Hamilton Company Thermo Fisher Scientific OCTANE BIOTECH

Market segmentation, by product types: Automated Cell Culture Storage Equipment Automated Cell Culture Vessels Automated Cell Culture Supporting Instruments Bioreactors

Market segmentation, by applications: Drug Development Stem Cell Research Cancer Research

Market segmentation, by regions: North America Europe Asia Pacific Middle East & Africa Latin America

In this report, we analyze the Automated Cell Culture industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a prediction of its production and consumption in coming 2019-2024.

At the same time, we classify different Automated Cell Culture based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Automated Cell Culture industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

The report can answer the following questions: 1. What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Automated Cell Culture? 2. Who are the global key manufacturers of Automated Cell Culture industry? How are their operating situation (capacity, production, price, cost, gross and revenue)? 3. What are the types and applications of Automated Cell Culture? What is the market share of each type and application? 4. What are the upstream raw materials and manufacturing equipment of Automated Cell Culture? What is the manufacturing process of Automated Cell Culture? 5. Economic impact on Automated Cell Culture industry and development trend of Automated Cell Culture industry. 6. What will the Automated Cell Culture market size and the growth rate be in 2024? 7. What are the key factors driving the global Automated Cell Culture industry? 8. What are the key market trends impacting the growth of the Automated Cell Culture market? 9. What are the Automated Cell Culture market challenges to market growth? 10. What are the Automated Cell Culture market opportunities and threats faced by the vendors in the global Automated Cell Culture market?

Purchase the research report @ https://www.abrreports.com/industry-insights/global-automated-cell-culture-industry-market-research-2019/checkout?option=one

Table of Contents 1 Industry Overview of Automated Cell Culture 2 Industry Chain Analysis of Automated Cell Culture 3 Manufacturing Technology of Automated Cell Culture 4 Major Manufacturers Analysis of Automated Cell Culture 5 Global Productions, Revenue and Price Analysis of Automated Cell Culture by Regions, Manufacturers, Types and Applications 6 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Automated Cell Culture 2014-2019 7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis of Automated Cell Culture by Regions 8 Gross and Gross Margin Analysis of Automated Cell Culture 9 Marketing Traders or Distributor Analysis of Automated Cell Culture 10 Global and Chinese Economic Impacts on Automated Cell Culture Industry 11 Development Trend Analysis of Automated Cell Culture 12 Contact information of Automated Cell Culture 13 New Project Investment Feasibility Analysis of Automated Cell Culture 14 Conclusion of the Global Automated Cell Culture Industry 2019 Market Research Report

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company that offers market research reports to individuals, organizations, and industries to enhance and strengthen the decision making process. With an associate thoroughgoing list of market research Publishers, we tend to cut across all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trends, information on products, regional market, and keen business insights to our clients.

Contact Us:

Scott Harris Sales Manager Email ID: [emailprotected] Phone No.: +1-561-448-7424

View post:
Impact Of Covid-19 Outbreak On Global Automated Cell Culture Market Segment Analysis and 2020-2024 Future Projection Level - The Daily Chronicle

Genetic mutations may be linked to infertility, early menopause – Washington University School of Medicine in St. Louis

Visit the News Hub

Gene in fruit flies, worms, zebrafish, mice and people may help explain some fertility issues

Researchers at Washington University School of Medicine in St. Louis have identified a gene that plays an important role in fertility across multiple species. Pictured is a normal fruit fly ovary (left) and a fruit fly ovary with this gene dialed down (right). Male and female animals missing this gene had substantially defective reproductive organs. The study could have implications for understanding human infertility and early menopause.

A new study from Washington University School of Medicine in St. Louis identifies a specific genes previously unknown role in fertility. When the gene is missing in fruit flies, roundworms, zebrafish and mice, the animals are infertile or lose their fertility unusually early but appear otherwise healthy. Analyzing genetic data in people, the researchers found an association between mutations in this gene and early menopause.

The study appears Aug. 28 in the journal Science Advances.

The human gene called nuclear envelope membrane protein 1 (NEMP1) is not widely studied. In animals, mutations in the equivalent gene had been linked to impaired eye development in frogs.

The researchers who made the new discovery were not trying to study fertility at all. Rather, they were using genetic techniques to find genes involved with eye development in the early embryos of fruit flies.

We blocked some gene expression in fruit flies but found that their eyes were fine, said senior author Helen McNeill, PhD, the Larry J. Shapiro and Carol-Ann Uetake-Shapiro Professor and a BJC Investigator at the School of Medicine. So, we started trying to figure out what other problems these animals might have. They appeared healthy, but to our surprise, it turned out they were completely sterile. We found they had substantially defective reproductive organs.

Though it varied a bit by species, males and females both had fertility problems when missing this gene. And in females, the researchers found that the envelope that contains the eggs nucleus the vital compartment that holds half of an organisms chromosomes looked like a floppy balloon.

This gene is expressed throughout the body, but we didnt see this floppy balloon structure in the nuclei of any other cells, said McNeill, also a professor of developmental biology. That was a hint wed stumbled across a gene that has a specific role in fertility. We saw the impact first in flies, but we knew the proteins are shared across species. With a group of wonderful collaborators, we also knocked this gene out in worms, zebrafish and mice. Its so exciting to see that this protein that is present in many cells throughout the body has such a specific role in fertility. Its not a huge leap to suspect it has a role in people as well.

To study this floppy balloon-like nuclear envelope, the researchers used a technique called atomic force microscopy to poke a needle into the cells, first penetrating the outer membrane and then the nucleuss membrane. The amount of force required to penetrate the membranes gives scientists a measure of their stiffness. While the outer membrane was of normal stiffness, the nucleuss membrane was much softer.

Its interesting to ask whether stiffness of the nuclear envelope of the egg is also important for fertility in people, McNeill said. We know there are variants in this gene associated with early menopause. And when we studied this defect in mice, we see that their ovaries have lost the pool of egg cells that theyre born with, which determines fertility over the lifespan. So, this finding provides a potential explanation for why women with mutations in this gene might have early menopause. When you lose your stock of eggs, you go into menopause.

On the left is a normal fruit fly ovary with hundreds of developing eggs. On the right is a fruit fly ovary that is totally missing the NEMP gene. It is poorly developed and no eggs are visible.

McNeill and her colleagues suspect that the nuclear envelope has to find a balance between being pliant enough to allow the chromosomes to align as they should for reproductive purposes but stiff enough to protect them from the ovarys stressful environment. With age, ovaries develop strands of collagen with potential to create mechanical stress not present in embryonic ovaries.

If you have a softer nucleus, maybe it cant handle that environment, McNeill said. This could be the cue that triggers the death of eggs. We dont know yet, but were planning studies to address this question.

Over the course of these studies, McNeill said they found only one other problem with the mice missing this specific gene: They were anemic, meaning they lacked red blood cells.

Normal adult red blood cells lack a nucleus, McNeill said. Theres a stage when the nuclear envelope has to condense and get expelled from the young red blood cell as it develops in the bone marrow. The red blood cells in these mice arent doing this properly and die at this stage. With a floppy nuclear envelope, we think young red blood cells are not surviving in another mechanically stressful situation.

The researchers would like to investigate whether women with fertility problems have mutations in NEMP1. To help establish whether such a link is causal, they have developed human embryonic stem cells that, using CRISPR gene-editing technology, were given specific mutations in NEMP1 listed in genetic databases as associated with infertility.

We can direct these stem cells to become eggs and see what effect these mutations have on the nuclear envelope, McNeill said. Its possible there are perfectly healthy women walking around who lack the NEMP protein. If this proves to cause infertility, at the very least this knowledge could offer an explanation. If it turns out that women who lack NEMP are infertile, more research must be done before we could start asking if there are ways to fix these mutations restore NEMP, for example, or find some other way to support nuclear envelope stiffness.

This work was supported by the Canadian Institutes of Health, research grant numbers 143319, MOP-42462, PJT-148658, 153128, 156081, MOP-102546, MOP-130437, 143301, and 167279. This work also was supported, in part, by the Krembil Foundation; the Canada Research Chair program; the National Institutes of Health (NIH), grant number R01 GM100756; and NSERC Discovery grant; and the Medical Research Council, unit programme MC_UU_12015/2. Financial support also was provided by the Wellcome Senior Research Fellowship, number 095209; Core funding 092076 to the Wellcome Centre for Cell Biology; a Wellcome studentship; the Ontario Research FundsResearch Excellence Program. Proteomics work was performed at the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government, and by the Genome Canada and Ontario Genomics, grant numbers OGI-097 and OGI-139.

Tsatskis Y, et al. The NEMP family supports metazoan fertility and nuclear envelope stiffness. Science Advances. Aug. 28, 2020.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Continued here:
Genetic mutations may be linked to infertility, early menopause - Washington University School of Medicine in St. Louis

Equipping the Immune System to Fight Against COVID-19 – BioSpace

The coronavirus that causes COVID-19 has one major advantage over us it is a new human virus. Most people have not encountered the virus before, meaning their immune system is not primed and ready to fight it. When someone gets sick with COVID-19, there is a lag in an efficient immune response, giving the virus time to do significant damage before the immune system can reign in the infection.

It essentially becomes a race between how fast your immune system can clear the virus and how quickly the virus can replicate and induce damage, Agustin Melian, MD, Chief Medical Officer and Head of Global Medical Sciences at AlloVir, told BioSpace.

To develop an effective treatment or vaccine for COVID-19, scientists must understand how the immune system is impacted during the disease. One type of immune cell that is particularly important in the bodys response to COVID-19 is T-cells. T-cells perform many functions, including recognizing invading viruses such as the coronavirus that causes COVID-19.

Multiple studies from Wuhan, China reported that COVID-19 patients had very low T-cell counts; the sicker the patient, the lower their T-cell count. Lower T-cell counts were correlated with poorer outcomes (including higher risk of death) and T-cells isolated from COVID-19 patients also showed signs of exhaustion.

The elderly, patients with low T-cell numbers, and patients who express exhaustion markers on their T-cells are high risk groups in which nave cell responses (responses against a virus they have never seen before) may be deficient or delayed, thus allowing the virus to induce a large amount of damage, Dr. Melian explained. These patients may, therefore, benefit from AlloVirs approach which is designed to restore natural T-cell immunity in high risk patients.

Could giving high-risk COVID-19 patients functional T-cells against the coronavirus boost their immune system and help them recover? This is the question AlloVir aims to answer.

AlloVir creates allogeneic (off-the-shelf) virus-specific T-cells designed to treat common and devastating viral-associated diseases in vulnerable patients, such as those who are immunocompromised or patients who received an organ or stem cell transplant. Now, they are expanding their anti-viral T-cell arsenal and taking aim at COVID-19.

We believe AlloVirs technology is well positioned to treat patients with COVID-19 because our technology is designed to provide SARS-CoV-2 specific T-cell immunity while leaving non-infected cells intact, Dr. Melian commented. Our virus-specific T-cell candidates have been used to treat more than 275 immunocompromised patients with life-threatening viral infections and diseases and we believe it our approach may also have promise in treating COVID-19.

Fighting viruses with T-cells in immunocompromised patients

When you get infected with a virus, your immune system responds to the foreign threat by making specific T-cells that can recognize the virus. These specific T-cells prompt your immune system to destroy any cells infected by the virus.

However, if you have a T-cell deficiency, your immune system cannot robustly protect you. This is a major problem because an otherwise innocuous virus can become a serious infection, causing complications, and possibly even be life-threatening.

That is where AlloVir comes in. They address the underlying problem the weakened immune system. A weakened immune system can be beefed up by giving patients with T-cell deficiencies off-the-shelf virus-specific T-cells (VSTs) originally taken from healthy people. This restores their natural T-cell immunity and helps their immune system fight off the viruses.

At AlloVir, we are a leading innovator in discovering and developing allogeneic, virus-specific T-cell immunotherapies, Dr. Melian said. We are now excited to be applying our capabilities in discovering and developing SARS-CoV-2 specific T-cells to join the fight in developing a COVID-19 program for patients at high risk of severe and devastating disease.

AlloVirs virus-specific T-cell platform

To create AlloVirs T-cell therapies, the target virus is first studied carefully to identify its specific antigens (unique molecules on the outside of each virus that are specific to the virus and alert the immune system). The best antigens those that induce a strong T-cell response are used to create the therapy.

Next, blood is taken from healthy donors who have been exposed to the virus of interest and T-cells are isolated from the blood. The T-cells are activated in the lab they are trained to recognize the identified viral antigens, enabling the T-cells to selectively recognize only the desired virus.

After the T-cells have learned to recognize the specific virus, they are expanded to generate multitudes of cells. Once the activated, specific T-cells are created, they can be cryopreserved and kept for a long time, making them readily available as soon as a patient needs them. The entire process, from antigen selection to donor to ready-to-go T-cell treatment, can be completed in a matter of weeks. This process can be seen in the visual below.

Source: AlloVir

Patients are matched using the companys proprietary human leukocyte antigen (HLA)-matching formula. HLAs are proteins on the surface of cells that regulate the immune system.

Our proprietary donor selection algorithm, known as Cytokin enables us to cover >95 percent of patients in our target population from cells derived from a small number of donors, Dr. Melian said. This proprietary process of prospectively manufacturing cells for off-the-shelf use enables us to study our allogeneic cell therapies in large numbers of patients that suffer from global health crises, like seasonal influenza and, as we are discussing, the COVID-19 pandemic.

These T-cells are advantageous because they are active against a single virus or multiple viruses, are not patient-specific (so they are readily available) and are a single treatment that provides lasting protection. The biggest bonus is the immediate off-the-shelf use for time-sensitive infections in vulnerable populations, added Dr. Melian.

In addition to developing their COVID-19 therapy (called ALVR109), AlloVir has two other multi-virus specific T-cell therapies in development: Viralym-M (ALVR105) and ALVR106. Both therapies focus on treating viral diseases common to stem cell and solid organ transplant patients and other vulnerable populations.

Viralym-M targets six common viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV, also called human herpesvirus 4), human herpesvirus 6, and JC virus (also called human polyomavirus 2). Although these viruses are widespread and infect most people, they only cause severe problems in people with weakened immune systems due to age, organ or stem cell transplant, or disease (such as diabetes or AIDS). In a Phase 2 study, 93 percent of 38 allogeneic stem cell transplant patients had a clinical response to Viralym-M treatment and functional Viralym-M cells lasted up to 12 weeks in the patients.

ALVR106 targets four common respiratory viruses: influenza, parainfluenza virus, respiratory syncytial virus (RSV), and human meta-pneumovirus (HMPV). While these viruses tend to cause mild to moderate respiratory illnesses, they can cause severe, life-threatening illness, especially in people with weakened immune systems. ALVR106 is still in preclinical development but clinical trials are expected to begin this year. Overall, AlloVir expects to have three new proof-of-concept (POC) Phase 1b/2 and three pivotal Phase 3 studies started over the next 6-18 months.

Off-the-shelf T-cells against COVID-19

While AlloVir originally designed their T-cell therapies for transplant patients, their platform can potentially be applied to any virus to create virus-specific T-cells. This versatility allowed AlloVir to pivot and create T-cells against SARS-CoV-2, the virus that causes COVID-19. This new investigational therapy, called ALVR109, is being developed as a stand-alone treatment, though it may also be incorporated into their ALVR106 respiratory virus therapy at some point in the future.

Normally, the body would make virus-specific T-cells on their own and these would clear the virus, commented Dr. Melian. We enable that process in patients who otherwise would be T-cell deficient to restore T-cell immunity by giving ex vivo expanded cells that come from patients who already have demonstrated a potent immune response and have cleared the infection.

The process of creating coronavirus-specific T-cells is the same as creating their other virus-specific T-cell therapies. First, blood is taken from people who have recovered from COVID-19 and the T-cells are isolated. Then, the cells are stimulated with viral antigens in the lab, expanded, and cryopreserved.

We purposely choose a broad range of viral antigens to stimulate the T-cells to ensure the virus cant circumvent the virus-specific T-cell therapy by mutating or developing resistance, Dr. Melian said. Working with a wide spectrum of viral activity is different than other approaches that just focus on one viral antigen.

An open-label Phase 1 trial (called BAT IT) is anticipated to start within the next few months. Initial clinical studies of ALVR109 aim to treat high-risk COVID-19 patients, such as the elderly, to prevent organ damage. Prophylaxis studies, where the T-cells could be given to high-risk or immunocompromised patients who are not currently sick with COVID-19, may be considered later.

Coronavirus-specific T-cells vs. COVID-19 convalescent plasma

You may be wondering if another treatment that uses blood from COVID-19 survivors, called convalescent plasma therapy, is similar to AlloVirs T-cell therapy. In convalescent plasma treatment, antibodies from COVID-19 survivors are isolated from their blood by separating out their plasma (the liquid part of the blood). The plasma is given to COVID-19 patients to help their immune system fight off the infection.

Although convalescent plasma and AlloVirs coronavirus-specific T-cell treatments are both derived from COVID-19 survivors blood, the two treatments are fundamentally different.

Antibodies and T-cells work in different areas of the immune system, explained Dr. Melian. Antibodies can go after viruses in circulating blood but cant necessarily see viruses in infected cells. On the other hand, T-cells are pleotropic and directly attack virally infected cells, turning off the viral factories. T-cells are interesting because it is a live therapy they can home to virally-infected cells and direct the immune system.

Dr. Melian went on to explain that T-cell approach may be more comprehensive because they can support other immune cells that work against viruses, such as B-cells that make viral-specific antibodies. T-cells can also stimulate cytokines including interferon (a group of signaling proteins the immune system uses to respond to viruses), which further activates the bodys antiviral response.

Providing virus-specific antibodies may be beneficial and protective for some viral infections, Dr. Melian added. We dont know how these antibodies affect COVID-19 patients yet, but COVID-19 has a high mortality rate despite standard of care treatment. In this respect, it is important that all viable approaches to treatment be evaluated and I am very pleased to see these therapies have entered clinical testing.

Convalescent plasma and AlloVirs coronavirus-specific T-cell therapies are not mutually exclusive, so they could even be used together.

See the original post here:
Equipping the Immune System to Fight Against COVID-19 - BioSpace